
NATALEE, DeLLphi-305, INTerpath-001, and LITESPARK-012 Headline Key Oncology Data From ESMO 2026
Key Takeaways
- Adjuvant ribociclib plus NSAI improved 6-year OS (HR 0.81) and IDFS (HR 0.74) versus NSAI alone in stage II–III HR+/HER2− disease, including node-negative intermediate-risk patients.
- First-line maintenance tarlatamab plus durvalumab after nonprogressing induction chemoimmunotherapy nearly doubled median OS (21.1 vs 12.7 months; HR 0.42) and improved PFS/ORR, with more grade ≥3 AEs.
Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.
Long-term overall survival (OS) data in early breast cancer, a new first-line maintenance strategy in extensive-stage small cell lung cancer (SCLC), an individualized neoantigen therapy in resected melanoma, and a negative phase 3 readout in advanced renal cell carcinoma (RCC) were among the presentations that shaped discussion at the
Throughout the meeting, OncLive® spoke with experts across tumor types about the data that stood out most to them. Below, revisit 4 of those presentations, including the top-line findings from each trial and expert perspective on their significance.
Breast Cancer
Adjuvant ribociclib (Kisqali) plus a nonsteroidal aromatase inhibitor (NSAI) improved OS vs an nonsteroidal aromatase inhibitor alone in patients with stage II or III hormone receptor–positive, HER2-negative early breast cancer at high risk of recurrence, according to findings from a prespecified 6-year analysis of the phase 3 NATALEE trial (NCT03701334).1
At a median follow-up of 66.5 months, the 6-year OS rate was 91.9% in the ribociclib arm (n = 2549) vs 89.7% in the control arm (n = 2552), translating to an absolute benefit of 2.1% (HR, 0.809; 95% CI, 0.661-0.989; nominal 1-sided P = .019). At the time of analysis, all patients had stopped ribociclib, with a median time off treatment of 38 months. The 6-year invasive disease–free survival rates were 83.2% vs 77.9%, respectively (HR, 0.741; 95% CI, 0.646-0.849; nominal 1-sided P < .0001), and breast cancer–specific survival also favored ribociclib (HR, 0.706; 95% CI, 0.559-0.890; nominal 1-sided P = .002). No new safety signals emerged.
"[These data are] on par with the phase 3 monarchE trial data, showing that we can change outcomes for patients with high- and intermediate-risk early-stage disease who receive a CDK4/6 inhibitor," Hope S. Rugo, MD, FASCO, director of the Women's Cancers Program, division chief of Breast Medical Oncology, and professor in the Department of Medical Oncology & Therapeutics Research at City of Hope, said in an interview with OncLive.2 "The NATALEE trial is important because of the inclusion of the intermediate-risk population that had node-negative disease."
Lung Cancer
First-line maintenance tarlatamab-dlle (Imdelltra) plus durvalumab (Imfinzi) improved OS, progression-free survival (PFS), and objective response rate (ORR) vs durvalumab alone in patients with extensive-stage small cell lung cancer whose disease had not progressed after first-line chemoimmunotherapy with durvalumab, according to primary results from the phase 3 DeLLphi-305 trial (NCT06211036).3
At a prespecified interim analysis, the median OS was 21.1 months (95% CI, 20.8-not estimable [NE]) with the combination (n = 282) vs 12.7 months (95% CI, 11.2-14.8) with durvalumab alone (n = 281; HR, 0.42; 95% CI, 0.32-0.54; P < .001). The median PFS values were 7.4 months (95% CI, 5.6-9.1) vs 1.9 months (95% CI, 1.9-2.0), respectively (HR, 0.34; 95% CI, 0.28-0.42; P < .001). Among patients with measurable disease, the ORRs were 26.4% (95% CI, 20.9%-32.5%; n = 235) vs 4.1% (95% CI, 2.0%-7.4%; n = 244; P < .001), respectively, and the median duration of response was 12.7 months (95% CI, 7.4-not estimable) vs 5.6 months (95% CI, 3.6-NE). Grade 3 or higher adverse effects (AEs) related to treatment occurred in 20.9% vs 10.8% of patients, respectively.
"What we've observed over the years is that tarlatamab has been showing promising efficacy, although, up until now, only in patients who have progressed on chemotherapy and immunotherapy," Marcelo Vailati Negrao, MD, assistant professor in the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston, said in an interview with OncLive.4 "We were excited to see the results of the first randomized trial of patients who had received chemoimmunotherapy without progression, who were subsequently randomly assigned to receive either durvalumab, which is one of our standard-of-care options, or durvalumab combined with tarlatamab. The benefit [with tarlatamab plus durvalumab] will be impactful."
Melanoma
The addition of the individualized neoantigen therapy intismeran autogene to pembrolizumab (Keytruda) improved recurrence-free survival (RFS) and distant metastasis–free survival (DMFS) vs placebo plus pembrolizumab in patients with resected stage IIB to IV melanoma, according to findings from the phase 3 INTerpath-001 trial (NCT05933577).5
At a median follow-up of 24.6 months, intismeran autogene plus pembrolizumab (n = 757) reduced the risk of recurrence or death by 42% vs placebo plus pembrolizumab (n = 380; HR, 0.58; 95% CI, 0.45-0.75; P < .001). The 24-month RFS rates were 82.2% (95% CI, 79.3%-84.8%) vs 70.0% (95% CI, 65.0%-74.5%), respectively. DMFS also favored the combination (HR, 0.62; 95% CI, 0.45-0.85; P = .002), with 24-month rates of 88.5% vs 80.2%. OS data were immature (HR, 0.77; 95% CI, 0.45-1.31; P = .33). Grade 3 or higher AEs occurred in 23.6% vs 20.3% of patients, respectively.
"We were all excited about seeing that a patient-specific neoantigen vaccine added to pembrolizumab made such a big difference in RFS and DMFS benefit," Dirk Schadendorf, MD, director and chair of the Department of Dermatology at University Hospital Essen and managing director of the West German Cancer Center in Essen, Germany, said in an interview with OncLive.6 "I believe that these mRNA vaccines will be a new step in oncology treatment over the next decade."
Kidney Cancer
Neither pembrolizumab plus lenvatinib (Lenvima) plus belzutifan (Welireg) nor coformulated pembrolizumab/quavonlimab plus lenvatinib improved PFS or OS vs pembrolizumab plus lenvatinib in patients with previously untreated advanced clear cell RCC, according to findings from the phase 3 LITESPARK-012 trial (NCT04736706).7
At a median follow-up of 43.6 months (range, 31.8-57.4), the median PFS was 20.8 months (95% CI, 17.9-23.7) with the belzutifan triplet (n = 560) vs 23.7 months (95% CI, 20.7-26.6) with the doublet (n = 566; HR, 1.08; 95% CI, 0.93-1.26; 1-sided P = .8408). The PFS HR for the quavonlimab regimen (n = 562) vs the doublet was 1.07 (95% CI, 0.92-1.25). The respective OS HRs were 1.04 (95% CI, 0.87-1.25) and 1.12 (95% CI, 0.94-1.35). The ORRs were 69.1%, 69.0%, and 76.3% in the belzutifan, quavonlimab, and doublet arms, respectively, and the complete response rates were 19.1%, 14.8%, and 14.8%.
"The reason I was particularly interested in this trial is it had the possibility of being a new, practice-changing trial," Benjamin Maughan, MD, PharmD, professor in the Division of Hematology and Oncology at the Joe R. and Teresa Lozano Long School of Medicine at The University of Texas at San Antonio and director of the Clinical Trials Office at Mays Cancer Center, said in an interview with OncLive.8 "Of course, it ended up being a negative trial in [that] the triplets were not superior to the doublet."
References
- Slamon DJ, Hortobagyi GN, Stroyakovskiy D, et al. Adjuvant ribociclib + nonsteroidal aromatase inhibitor in patients with HR+/HER2 early breast cancer: NATALEE 6-year overall survival and efficacy outcomes. Presented at: 2026 European Society for Medical Oncology Congress; October 23-27, 2026; Madrid, Spain. Abstract LBA25
- OncLive Staff. Breast cancer experts spotlight practice-informing and thought-provoking data from ESMO 2026. OncLive. November 3, 2026. Accessed November 17, 2026. https://www.onclive.com/view/breast-cancer-experts-spotlight-practice-informing-and-thought-provoking-data-from-esmo-2026
- Sands J, Yoshida T, Ahn MJ, et al. Tarlatamab plus durvalumab vs durvalumab as first-line maintenance therapy following first-line durvalumab, platinum, and etoposide in extensive-stage small cell lung cancer: primary analysis of the phase 3 DeLLphi-305 trial. Presented at: 2026 European Society for Medical Oncology Congress; October 23-27, 2026; Madrid, Spain. Abstract LBA3
- OncLive Staff. DLL3-targeted therapy and KRAS inhibition lead lung cancer data highlights from ESMO 2026. OncLive. November 4, 2026. Accessed November 17, 2026. https://www.onclive.com/view/dll3-targeted-therapy-and-kras-inhibition-lead-lung-cancer-data-highlights-from-esmo-2026
- Long GV, Khattak MA, Gogas HJ, et al. INTerpath-001: phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL). Presented at: 2026 European Society for Medical Oncology Congress; October 23-27, 2026; Madrid, Spain. Abstract LBA1
- OncLive Staff. Adjuvant intismeran autogene plus pembrolizumab data headline key melanoma findings from ESMO 2026. OncLive. November 6, 2026. Accessed November 17, 2026. https://www.onclive.com/view/adjuvant-intismeran-autogene-plus-pembrolizumab-data-headline-key-melanoma-findings-esmo-2026
- Choueiri TK, Powles TB, Voss MH, et al. First-line pembrolizumab + lenvatinib + belzutifan or MK-1308A + lenvatinib in advanced RCC: randomized open-label phase 3 LITESPARK-012 study. Presented at: 2026 European Society for Medical Oncology Congress; October 23-27, 2026; Madrid, Spain. Abstract 3586O
- OncLive Staff. LITESPARK-012, XmAb819, and PE-PE data headline key kidney cancer findings from ESMO 2026. OncLive. November 6, 2026. Accessed November 17, 2026. https://www.onclive.com/view/litespark-012-xmab819-and-pe-pe-data-headline-key-kidney-cancer-findings-from-esmo-2026
Related to this article








